• Roche partners with Vividion on novel E3 Ligases pharmatimes
    May 21, 2020
    Roche has signed up for access to Vividion Therapeutics' proteomics screening platform and proprietary small molecule library to target E3 ligases and a range of oncology and immunology therapeutic targets.
  • Roche enters $135m drug discovery deal with Vividion Therapeutics pharmaceutical-technology
    May 21, 2020
    Roche has signed an exclusive worldwide option and licence agreement with US-based biotechnology firm Vividion Therapeutics to discover and develop small molecules for various therapeutic targets.
PharmaSources Customer Service